New Delhi, 19 February, 2026: Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), to advance collaboration in pharmaceutical education and research.
The MoU was signed at the Department of Pharmaceuticals in the presence of Shri Manoj Joshi, IAS, Secretary, Department of Pharmaceuticals. Also present at the ceremony were Shri Awadhesh Kumar Choudhary, Senior Economic Advisor, Department of Pharmaceuticals, and Ms. Anugraha P, Director, Department of Pharmaceuticals.
The agreement establishes a framework for academic and research collaboration in pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchange, and capability-building programmes. The partnership will also explore opportunities to organise symposia, conferences, short-term courses, and scholar engagement initiatives to strengthen scientific exchange.
As part of the MoU, Boehringer Ingelheim will enable NIPER Raebareli to access opnMe®, the company’s open science portal designed to connect with researchers and institutions to accelerate scientific progress and healthcare innovation.
Meenal Gauri, Managing Director, Boehringer Ingelheim India, said, “India is entering an important phase in its pharmaceutical journey, moving from scale-led growth to innovation-led impact. At Boehringer Ingelheim, we believe progress in healthcare is accelerated when industry, academia, and public institutions come together. This MoU with NIPER Raebareli reflects our commitment to strengthening scientific capability and supporting collaborations that can contribute to better health outcomes for patients and communities.”
Prof. Shubhini A. Saraf, Director, NIPER Raebareli, added, “This MoU supports our vision of advancing pharmaceutical education and research while enabling opportunities for students and researchers to contribute to areas of emerging importance such as novel drug delivery systems and community health solutions. We look forward to working with Boehringer Ingelheim to create meaningful opportunities for students and researchers and to contribute to India’s innovation ecosystem.”
The collaboration aligns with India’s broader efforts to transition its pharmaceutical sector from a volume-driven and generic-led model to a more innovation-focused and research-driven ecosystem. Strengthening industry-academia linkages is seen as a key component of this shift, supporting the country’s long-term healthcare and innovation goals under the Viksit Bharat 2047 vision.
By creating structured engagement between academic research and industry expertise, the partnership aims to contribute to the development of skilled scientific talent and research pathways that can support more effective and patient-centric healthcare solutions over time.
x
.jpg)
